HUP9904525A2 - S-(-)-N-Propargil-1-amino-indán tartalmú neurológiai rendellenességek kezelésére alkalmas gyógyszerkészítmények - Google Patents

S-(-)-N-Propargil-1-amino-indán tartalmú neurológiai rendellenességek kezelésére alkalmas gyógyszerkészítmények

Info

Publication number
HUP9904525A2
HUP9904525A2 HU9904525A HUP9904525A HUP9904525A2 HU P9904525 A2 HUP9904525 A2 HU P9904525A2 HU 9904525 A HU9904525 A HU 9904525A HU P9904525 A HUP9904525 A HU P9904525A HU P9904525 A2 HUP9904525 A2 HU P9904525A2
Authority
HU
Hungary
Prior art keywords
injury
propargyl
treatment
neurological disorders
pharmaceutical compositions
Prior art date
Application number
HU9904525A
Other languages
English (en)
Inventor
Sasson Cohen
John P. M. Finberg
Ruth Levy
Jeff Sterling
Moussa B. H. Youdim
Original Assignee
Technion Research And Development Foundation Ltd.
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research And Development Foundation Ltd., Teva Pharmaceutical Industries Ltd. filed Critical Technion Research And Development Foundation Ltd.
Publication of HUP9904525A2 publication Critical patent/HUP9904525A2/hu
Publication of HUP9904525A3 publication Critical patent/HUP9904525A3/hu
Publication of HU226961B1 publication Critical patent/HU226961B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

NCS = (57) Neurológiai rendellenességek vagy neurotrauma kezelésére,vagy a memória javítására szolgáló gyógyszerkészítmény, különösen acentrális vagy periferiális idegrendszer károsodását okozó isémiáskárosodás, agyvérzés, hipoxia vagy anoxia, neurodegeneratívbetegségek, Parkinson-kór, Alzheimer- kór, neurotoxikus sérülés,fejsérülés okozta trauma, károsodás, spinális sérülés okozta traumavagy bármely más alakban megjelenő idegkárosodás esetén, amelyhatóanyagként S-(-)-N-propargil-1-amino-indánt vagy annakgyógyszerészeti szempontból elfogadható sóját tartalmazza valamelygyógyszerészeti hordozó- vagy más segédanyag mellett. Ó
HU9904525A 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan HU226961B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11883696A IL118836A (en) 1996-07-11 1996-07-11 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
PCT/IL1997/000205 WO1998002152A1 (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan

Publications (3)

Publication Number Publication Date
HUP9904525A2 true HUP9904525A2 (hu) 2000-11-28
HUP9904525A3 HUP9904525A3 (en) 2000-12-28
HU226961B1 HU226961B1 (en) 2010-03-29

Family

ID=11069065

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904525A HU226961B1 (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan

Country Status (12)

Country Link
US (1) US6277886B1 (hu)
EP (1) EP0929298B1 (hu)
JP (1) JP4368421B2 (hu)
CN (1) CN1149985C (hu)
AT (1) ATE328590T1 (hu)
AU (1) AU3188097A (hu)
CA (1) CA2260037C (hu)
DE (1) DE69736066T2 (hu)
HU (1) HU226961B1 (hu)
IL (1) IL118836A (hu)
NO (1) NO326052B1 (hu)
WO (1) WO1998002152A1 (hu)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
JP2004537506A (ja) 2001-03-01 2004-12-16 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 血液細胞欠乏症を治療するためのある種のステロイドの使用
WO2004019953A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
AU2003282337B2 (en) * 2002-11-07 2009-07-16 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
SI1567152T1 (sl) 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
WO2005051371A1 (en) * 2003-11-25 2005-06-09 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
US20060025446A1 (en) * 2004-07-27 2006-02-02 Jeffrey Sterling Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
EP2471536A1 (en) 2004-09-29 2012-07-04 Harbor BioSciences, Inc. Steroid analogs and characterization and treatment methods
SI1848415T1 (sl) * 2005-02-17 2013-08-30 Teva Pharmaceutical Industries Ltd. Kombinacijska terapija z glatiramer acetatom in razagilinom za zdravljenje muliple skleroze
BRPI0608209A2 (pt) 2005-02-23 2010-11-09 Teva Pharma mistura de partìculas, composição sólida, método para tratamento de um paciente com mal de parkinson, processo para preparação de uma composição, e, composição farmacêutica sólida
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
JP2009521402A (ja) * 2005-11-17 2009-06-04 テバ ファーマシューティカル インダストリーズ リミティド プロパルギル化アミノインダンの分離のための方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP2009518433A (ja) * 2005-12-09 2009-05-07 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム 神経保護用の低用量ラドスチギルの使用
US8809310B2 (en) 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
CN101442997B (zh) 2006-04-03 2012-11-14 泰华制药工业有限公司 雷沙吉兰用于治疗多动腿综合征
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
JP5623081B2 (ja) * 2006-12-14 2014-11-12 テバ ファーマシューティカル インダストリーズ リミティド 結晶質固体のラサジリン塩基
CA2672452C (en) * 2006-12-14 2012-07-03 Teva Pharmaceutical Industries Ltd. Tannate salt of rasagiline
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
JP2010538067A (ja) * 2007-09-05 2010-12-09 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンを使用する緑内障の治療方法
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
MX2010007601A (es) * 2008-01-11 2010-08-03 Teva Pharma Formulaciones de rasagilina, su preparacion y uso.
US20110027354A1 (en) * 2008-04-01 2011-02-03 Kim Hyoung-Chun Anti-parkinsonian compounds
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
CN102065687A (zh) * 2008-06-13 2011-05-18 泰华制药工业有限公司 雷沙吉兰用于改善帕金森氏症
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
CN102065853A (zh) * 2008-06-19 2011-05-18 泰华制药工业有限公司 制备和干燥固体雷沙吉兰碱的方法
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
JP6045347B2 (ja) 2010-02-03 2016-12-14 ファーマ ツー ビー リミテッド ラサギリンの持続放出性製剤およびその使用
RU2013108256A (ru) 2010-07-27 2014-09-10 Тева Фармасьютикал Индастриз Лтд. Дисперсии цитрата разагилина
CA2806740A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
KR20140084153A (ko) 2011-10-10 2014-07-04 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-메틸-프로파길-아미노인단
BR112014008555A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-formil-propargil-aminoindano
AR092168A1 (es) 2012-08-17 2015-03-25 Teva Pharma Formulaciones parenterales de rasagilina
CN104177611A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN104177610A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN111333517A (zh) * 2018-12-19 2020-06-26 上海奥博生物医药技术有限公司 一种制备雷沙吉兰的改进方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
CA2180841C (en) * 1994-01-10 2007-03-27 Sasson Cohen 1-aminoindan derivatives and compositions thereof
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

Also Published As

Publication number Publication date
EP0929298B1 (en) 2006-06-07
CA2260037A1 (en) 1998-01-22
ATE328590T1 (de) 2006-06-15
NO990088L (no) 1999-03-10
JP2000514453A (ja) 2000-10-31
AU3188097A (en) 1998-02-09
WO1998002152A1 (en) 1998-01-22
DE69736066T2 (de) 2006-12-28
HUP9904525A3 (en) 2000-12-28
HU226961B1 (en) 2010-03-29
JP4368421B2 (ja) 2009-11-18
IL118836A0 (en) 1996-10-31
NO990088D0 (no) 1999-01-08
US6277886B1 (en) 2001-08-21
CN1149985C (zh) 2004-05-19
CA2260037C (en) 2007-01-23
CN1227486A (zh) 1999-09-01
DE69736066D1 (de) 2006-07-20
IL118836A (en) 2001-01-11
NO326052B1 (no) 2008-09-08
EP0929298A1 (en) 1999-07-21

Similar Documents

Publication Publication Date Title
HUP9904525A2 (hu) S-(-)-N-Propargil-1-amino-indán tartalmú neurológiai rendellenességek kezelésére alkalmas gyógyszerkészítmények
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
NL300205I1 (nl) N-enentiomeer van N-propargyl-1-aminoindaan voor de behandeling van verschillende ziekten, en mesylaat, esylaat en sulfaat daarvan.
CA2031714A1 (en) R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
WO1996037199A8 (en) Use of r-enantiomer of n-propargyl-1-aminoindan, salts, and compositions thereof
PT96930A (pt) Metodo para a utilizacao de guanidinas tri- e tetra-substituidas como antagonistas de amino-acidos excitadores
WO1988009789A2 (en) 3-indolepyruvic acid derivatives and pharmaceutical use thereof
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
RU2003124059A (ru) Лечение неврологической дисфункции с применением сульфаматов фруктопиранозы и эритропоэтина
RU96105707A (ru) Лекарственное средство для лечения дегенеративных заболеваний нервной системы
YU49215B (sh) Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja
TW197423B (hu)
ATE325610T1 (de) Xanthinderivative zur behandlung von hirnischämie
AP2002002697A0 (en) Biciclic cyclohexylamines and their use as NMDA receptor antagonists.
BG102080A (en) Amino acid derivatives of substituted quinoxalin 2,3-dion derivatives such as glutamate receptor antagonists
GR3006606T3 (hu)
WO2001083449A3 (en) Rigid pyrrolidone modulators of pkc
WO2000056336A3 (en) Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin
MXPA01009385A (es) Compuestos de triazolopirimidinol y sales de los mismos.